Adma Biologics (ADMA) Other Non-Current Liabilities (2012 - 2025)
Adma Biologics (ADMA) posted Other Non-Current Liabilities of $90000.0 for Q3 2025, up 4400.0% on a QoQ basis from $2000.0 in Q2 2025, and down 76.0% year-over-year from $375000.0 in Q3 2024.
Adma Biologics (ADMA) Other Non-Current Liabilities (2012 - 2025) Analysis & Trends
Adma Biologics' Other Non-Current Liabilities history runs 13 years deep, the most recent figure standing at $90000.0 for Q3 2025.
- Quarterly Other Non-Current Liabilities fell 76.0% year-over-year to $90000.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $90000.0 (down 76.0% YoY) and the FY2024 annual result came in at $360000.0, down 14.08% from the prior year.
- Other Non-Current Liabilities was $90000.0 for Q3 2025 at Adma Biologics, up from $2000.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $449513.0 in Q2 2023 and bottomed at $2000.0 in Q1 2025.
- A 5-year average of $286617.5 and a median of $362179.0 in 2022 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2022 — Other Non-Current Liabilities jumped 934.28% — and 2025, when it sank 99.51%.
- Adma Biologics' Other Non-Current Liabilities stood at $397351.0 in 2021, then fell by 11.92% to $350000.0 in 2022, then increased by 19.71% to $419000.0 in 2023, then declined by 14.08% to $360000.0 in 2024, then plunged by 75.0% to $90000.0 in 2025.
- Business Quant data shows ADMA's Other Non-Current Liabilities at $90000.0 in Q3 2025, $2000.0 in Q2 2025, and $2000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Adma Biologics | 1.99 Bn | 1.91 Bn | 88.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 90,000.00 |
| Jun 30, 2025 | 2,000.00 |
| Mar 31, 2025 | 2,000.00 |
| Dec 31, 2024 | 360,000.00 |
| Sep 30, 2024 | 375,000.00 |
| Jun 30, 2024 | 390,000.00 |
| Mar 31, 2024 | 405,000.00 |
| Dec 31, 2023 | 419,000.00 |
| Sep 30, 2023 | 434,647.00 |
| Jun 30, 2023 | 449,513.00 |
| Mar 31, 2023 | 338,731.00 |
| Dec 31, 2022 | 350,000.00 |
| Sep 30, 2022 | 362,179.00 |
| Jun 30, 2022 | 373,903.00 |
| Mar 31, 2022 | 385,628.00 |
| Dec 31, 2021 | 397,351.00 |
| Sep 30, 2021 | 232,665.00 |
| Jun 30, 2021 | 36,151.00 |
| Mar 31, 2021 | 41,965.00 |
| Dec 31, 2020 | 54,886.00 |